This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1999 Dec 10;1489(1):97-106.

doi: 10.1016/s0167-4781(99)00139-6.

Human Bcl-2 antisense therapy for lymphomas

F E Cotter¹, J Waters, D Cunningham

Affiliations

PMID: 10807000
DOI: 10.1016/s0167-4781(99)00139-6

Review

Human Bcl-2 antisense therapy for lymphomas

F E Cotter et al. Biochim Biophys Acta. 1999.

. 1999 Dec 10;1489(1):97-106.

doi: 10.1016/s0167-4781(99)00139-6.

Authors

F E Cotter¹, J Waters, D Cunningham

Affiliation

¹ Division of Cancer Biology, Institute of Child Health, London, UK. f.cotter@ich.ucl.ac.uk

PMID: 10807000
DOI: 10.1016/s0167-4781(99)00139-6

No abstract available

PubMed Disclaimer

Similar articles

Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
[No authors listed] [No authors listed] Drugs R D. 2007;8(5):321-34. doi: 10.2165/00126839-200708050-00006. Drugs R D. 2007. PMID: 17767397 Review.
Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
Klasa RJ. Klasa RJ. Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):25-31. Oncology (Williston Park). 2004. PMID: 15651174 Review.
[Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)--review of preclinical and clinical results].
Büchele T. Büchele T. Onkologie. 2003 Dec;26 Suppl 7:60-9. doi: 10.1159/000076177. Onkologie. 2003. PMID: 14716145 Review. German.
Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts.
Smith MR, Jin F, Joshi I. Smith MR, et al. Mol Cancer Ther. 2004 Dec;3(12):1693-9. Mol Cancer Ther. 2004. PMID: 15634664
Potential therapeutic applications of oblimersen in CLL.
Koziner B. Koziner B. Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):32-8. Oncology (Williston Park). 2004. PMID: 15651175 Review.

See all similar articles

Cited by

Targeting the B-cell lymphoma/leukemia 2 family in cancer.
Davids MS, Letai A. Davids MS, et al. J Clin Oncol. 2012 Sep 1;30(25):3127-35. doi: 10.1200/JCO.2011.37.0981. Epub 2012 May 29. J Clin Oncol. 2012. PMID: 22649144 Free PMC article. Review.
Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer.
Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, Schuppan D. Ocker M, et al. Gut. 2005 Sep;54(9):1298-308. doi: 10.1136/gut.2004.056192. Gut. 2005. PMID: 16099798 Free PMC article.
miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.
Karaayvaz M, Zhai H, Ju J. Karaayvaz M, et al. Cell Death Dis. 2013 Jun 6;4(6):e659. doi: 10.1038/cddis.2013.193. Cell Death Dis. 2013. PMID: 23744359 Free PMC article.
Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?
Brinkmann K, Kashkar H. Brinkmann K, et al. Cell Death Dis. 2014 Mar 6;5(3):e1098. doi: 10.1038/cddis.2014.61. Cell Death Dis. 2014. PMID: 24603326 Free PMC article. Review.
Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.
Brem EA, Thudium K, Khubchandani S, Tsai PC, Olejniczak SH, Bhat S, Riaz W, Gu J, Iqbal A, Campagna R, Knight J, Mavis C, Hoskin P, Deeb G, Gibbs JF, Fetterly G, Czuczman MS, Hernandez-Ilizaliturri FJ. Brem EA, et al. Br J Haematol. 2011 Jun;153(5):599-611. doi: 10.1111/j.1365-2141.2011.08669.x. Epub 2011 Apr 15. Br J Haematol. 2011. PMID: 21492126 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database